SelectQuote Receives NYSE Non-Compliance Notice, Outlines Strategic and Financial Position

Key Highlights

• NYSE Non-Compliance Notice: SelectQuote, Inc. (NYSE: SLQT) has received a notification from the New York Stock Exchange (NYSE) that it is no longer in compliance with Section 802.01C of the NYSE Listed Company Manual. This is due to the company’s average closing price falling below \$1.00 per share over a consecutive 30 trading-day period.
• Strong Recent Financials: The company recently reported robust results for its fiscal second quarter 2026 and projects fiscal 2026 operating cash flow between \$25 million and \$35 million, with expectations for continued meaningful cash flow growth in the years ahead.
• Refinanced Debt: Earlier in the year, SelectQuote secured a new \$415 million credit facility, extending the majority of its debt maturities to 2031.
• Plans to Regain Compliance: SelectQuote has notified the NYSE of its intent to cure the stock price deficiency within the allowed six-month cure period, and will continue to monitor its stock price and take appropriate actions to maintain its listing.
• Business Will Continue as Usual: SelectQuote’s shares will remain listed and traded on the NYSE during the cure period, provided the company remains in compliance with other listing standards.

Details Investors Need to Know

Non-Compliance Implications:
The NYSE notice indicates a risk of delisting if the company is unable to restore its share price to above \$1.00 for a sustained period. This is a potentially price-sensitive development that could affect investor sentiment and SelectQuote’s market value. The company can regain compliance if, on the last trading day of any calendar month during the cure period, its stock closes at or above \$1.00 per share and maintains an average closing price of at least \$1.00 over the preceding 30 trading days.

Management’s Response:
SelectQuote has proactively communicated its intention to cure the deficiency and has highlighted its strong liquidity position, positive cash flow outlook, and operational flexibility as mitigating factors. Management is closely monitoring the share price and is prepared to take additional actions if required.

Financial Position and Strategic Direction:
The company’s new \$415 million credit facility not only extends the majority of its debt maturities to 2031 but also strengthens its liquidity profile. The fiscal 2026 operating cash flow guidance of \$25–\$35 million underpins management’s confidence in the company’s ability to fund its operations and strategic initiatives. SelectQuote expects this positive cash flow trajectory to continue in subsequent years.

Forward-Looking Risks:
The company’s forward-looking statements acknowledge several risks, including the ability to regain compliance with NYSE standards, continued competition, reliance on key insurance carrier partnerships, ongoing regulatory changes in the health insurance and pharmacy sectors, and potential disruptions related to its financial and operational infrastructure. Investors should be aware of these uncertainties, as they could have a material impact on future performance and share price.

About SelectQuote

Founded in 1985, SelectQuote is a leader in providing unbiased comparisons of insurance products from highly-rated carriers. The company operates an ecosystem spanning insurance, pharmacy, and virtual care, with three core business lines: SelectQuote Senior (Medicare Advantage and Supplement plans), SelectQuote Healthcare Services (including SelectRx Pharmacy and chronic care management), and SelectQuote Life. The company’s unique value proposition is supported by its highly trained agent force and proprietary lead generation technology.

Shareholder Takeaways

• The NYSE non-compliance notice is a material event. It poses a risk of delisting if not addressed, but the company has a clear plan and strong financial footing to resolve the issue.
• SelectQuote’s liquidity, cash flow outlook, and extended debt maturities provide operational stability as it works toward regaining compliance.
• The company’s continued listing during the cure period should offer some reassurance, but investors should closely monitor management’s execution and any developments related to the share price and NYSE communication.
• Risks remain, including competitive, regulatory, and operational factors, all of which could impact results and share performance.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a licensed financial advisor before making any investment decisions. The information presented is based on company disclosures as of the date of publication and may be subject to change.

View SelectQuote, Inc. Historical chart here